Many individual investors have opted to invest in biotech ETFs and mutual funds. The XBI and SBIO funds have performed well because they focus more on small and mid-sized biotech companies. The IBB, which has emerged as something of a proxy for the industry for many investors, is weighted much more heavily to bigger, more proven biotech companies.The volatility of […]
Markets are rebounding today after a horrible beginning to the week. Looking in the biotech sector, I’m seeing a sea of green with very few blemishes. I’ve also been able to dig out a few great opportunities in the sector. Here they are…Gilead Sciences Is Likely To See Long Run GainsGilead Sciences, Inc. (NASDAQ: GILD)I’ve talked about Gilead Sciences quite […]
Gilead Sciences, Inc. (GILD) Stock Update by Bidness ETC : Wednesday 11:44:23 CTCategories: News, streamGilead Sciences, Inc. (NASDAQ:GILD) has had an unimpressive month so far, which is unusual for a stock that happens to be one of the most traded biotech stocks in the market. The company’s stock has actually traded down 1.67% since the beginning of July, reaching a […]
It’s been a turbulent few days for the biotech sector with the NASDAQ Biotechnology Index declining 5.46% over the last five trading days. A major part of this decline was recorded on Monday as the sector reacted to negative pipeline updates from companies like Amgen (AMGN – Analyst Report) and Celladon (CLDN – Snapshot Report). Meanwhile, Biogen’s (BIIB – Analyst […]
Source: StockMonkeys.com via Flickr.It’s been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead’s share price tied to the approval of AbbVie ‘s Viekira Pak and its subsequent multi-year agreement with Express Scripts , Gilead shares are up 25% for the year, essentially doubling the return of the S&P 500 […]
Once again, deals and collaborations made news in the biotech sector with BioMarin (BMRN – Analyst Report) announcing its intention to acquire Prosensa (RNA – Snapshot Report) and Five Prime Therapeutics (FPRX – Snapshot Report) signing a second immuno-oncology focused deal with Bristol-Myers Squibb.Meanwhile, AbbVie (ABBV – Analyst Report) continues to progress with its hepatitis C virus (HCV) treatment with […]
